MX2021008651A - Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisomericamente enriquecido y metodo de preparacion y de purificacion. - Google Patents

Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisomericamente enriquecido y metodo de preparacion y de purificacion.

Info

Publication number
MX2021008651A
MX2021008651A MX2021008651A MX2021008651A MX2021008651A MX 2021008651 A MX2021008651 A MX 2021008651A MX 2021008651 A MX2021008651 A MX 2021008651A MX 2021008651 A MX2021008651 A MX 2021008651A MX 2021008651 A MX2021008651 A MX 2021008651A
Authority
MX
Mexico
Prior art keywords
complex
pcta
gadolinium
preparation
purification process
Prior art date
Application number
MX2021008651A
Other languages
English (en)
Inventor
Caroline Robic
Greneur Soizic Le
Alain Chénedé
Martine Cerf
Myriam Petta
Emmanuelle Marais
Bruno François
Stéphanie Louguet
Original Assignee
Guerbet Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet Sa filed Critical Guerbet Sa
Publication of MX2021008651A publication Critical patent/MX2021008651A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un complejo de fórmula (II) que consiste en al menos el 90% de un exceso diastereoisomérico que comprende una mezcla de isómeros II-RRR e II-SSS de fórmulas: (ver Fórmulas) (II-SSS) (II-RRR) la presente invención también se refiere a un proceso para la preparación y purificación de dicho complejo de fórmula (II), así como una composición que comprende dicho complejo.
MX2021008651A 2019-01-17 2020-01-17 Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisomericamente enriquecido y metodo de preparacion y de purificacion. MX2021008651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1900432A FR3091873B1 (fr) 2019-01-17 2019-01-17 Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
PCT/EP2020/051153 WO2020148436A1 (fr) 2019-01-17 2020-01-17 Complexe de gadolinium et d'un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification

Publications (1)

Publication Number Publication Date
MX2021008651A true MX2021008651A (es) 2021-10-26

Family

ID=67001953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008651A MX2021008651A (es) 2019-01-17 2020-01-17 Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisomericamente enriquecido y metodo de preparacion y de purificacion.

Country Status (27)

Country Link
US (2) US11590246B2 (es)
EP (2) EP3902800B1 (es)
JP (2) JP7071596B2 (es)
KR (2) KR102502862B1 (es)
CN (2) CN113646308A (es)
AR (1) AR117835A1 (es)
AU (1) AU2020208794B2 (es)
BR (1) BR112021014006B1 (es)
CA (1) CA3126268C (es)
CL (1) CL2021001868A1 (es)
CO (1) CO2021009261A2 (es)
DK (2) DK3943493T3 (es)
ES (2) ES2950118T3 (es)
FI (1) FI3943493T3 (es)
FR (1) FR3091873B1 (es)
HR (2) HRP20230678T1 (es)
HU (2) HUE060343T2 (es)
IL (1) IL284884A (es)
MA (2) MA55389A (es)
MX (1) MX2021008651A (es)
PL (2) PL3943493T3 (es)
PT (2) PT3902800T (es)
RS (1) RS64334B1 (es)
SG (1) SG11202107779SA (es)
TW (1) TWI811518B (es)
WO (1) WO2020148436A1 (es)
ZA (1) ZA202104994B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2938015T3 (es) 2018-08-06 2023-04-03 Bracco Imaging Spa Agentes de contraste basados en PCTA que comprenden gadolinio
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
EP4182314A1 (fr) * 2020-07-17 2023-05-24 Guerbet Procede de preparation d'un ligand chelateur derive de pcta
EP4222861A1 (en) * 2020-10-02 2023-08-09 Eagle Harbor Technologies, Inc. Ion current droop compensation
WO2024049087A1 (ko) * 2022-09-01 2024-03-07 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
JPH04154729A (ja) 1990-10-16 1992-05-27 Nippon Mejifuijitsukusu Kk 磁気共鳴造影剤
EP0992245A1 (en) 1998-09-16 2000-04-12 Goldham Bioglan Pharma GmbH Radio-contrast agents
FR2793795B1 (fr) * 1999-05-21 2001-08-03 Guerbet Sa Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
FR2794744B1 (fr) * 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US20090208421A1 (en) * 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
US8119817B2 (en) 2009-09-29 2012-02-21 Degussa-Huels Ag Process for separating the diastereomers of RSS-and SSS-N- α [1-carboxy-3-phenylpropyl] lysylproline
EP2786768A1 (en) * 2013-04-04 2014-10-08 Agfa Healthcare Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide
PL2988756T5 (pl) * 2013-04-26 2022-09-26 Guerbet Formulacja środka kontrastowego i powiązany sposób jego wytwarzania
CN104188957B (zh) 2014-05-28 2017-04-26 中国中医科学院西苑医院 一种防治再狭窄的药物及其制备和使用方法
NZ757747A (en) 2017-04-28 2022-04-29 Otsuka Pharma Factory Inc Method for manufacturing diastereomer of citric acid derivative
ES2938015T3 (es) * 2018-08-06 2023-04-03 Bracco Imaging Spa Agentes de contraste basados en PCTA que comprenden gadolinio
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification

Also Published As

Publication number Publication date
CA3126268A1 (fr) 2020-07-23
KR102438394B1 (ko) 2022-09-01
MA55389A (fr) 2022-01-26
ES2950118T3 (es) 2023-10-05
KR102502862B1 (ko) 2023-02-23
AU2020208794A1 (en) 2021-08-05
BR112021014006A2 (pt) 2021-09-21
ZA202104994B (en) 2023-04-26
AU2020208794B2 (en) 2023-01-12
US20230149568A1 (en) 2023-05-18
CN113735854B (zh) 2024-05-14
EP3902800B1 (fr) 2022-09-07
IL284884A (en) 2021-08-31
JP7321230B2 (ja) 2023-08-04
HUE062554T2 (hu) 2023-11-28
EP3943493A1 (fr) 2022-01-26
ES2930136T3 (es) 2022-12-07
PL3902800T3 (pl) 2022-12-27
JP2022009463A (ja) 2022-01-14
TWI811518B (zh) 2023-08-11
HUE060343T2 (hu) 2023-02-28
EP3943493B1 (fr) 2023-04-19
PL3943493T3 (pl) 2023-08-07
HRP20221402T1 (hr) 2023-01-06
EP3902800A1 (fr) 2021-11-03
MA54626A (fr) 2022-04-20
HRP20230678T1 (hr) 2023-09-29
CN113735854A (zh) 2021-12-03
US11590246B2 (en) 2023-02-28
AR117835A1 (es) 2021-08-25
CN113646308A (zh) 2021-11-12
JP7071596B2 (ja) 2022-05-19
FI3943493T3 (fi) 2023-07-19
BR112021014006B1 (pt) 2023-05-02
PT3943493T (pt) 2023-07-12
FR3091873B1 (fr) 2020-12-25
WO2020148436A1 (fr) 2020-07-23
CA3126268C (fr) 2024-01-09
DK3943493T3 (da) 2023-07-24
JP2022508496A (ja) 2022-01-19
KR20210138134A (ko) 2021-11-18
KR20210109039A (ko) 2021-09-03
CO2021009261A2 (es) 2021-12-10
SG11202107779SA (en) 2021-08-30
US20220062443A1 (en) 2022-03-03
DK3902800T3 (da) 2022-11-28
CL2021001868A1 (es) 2022-01-21
FR3091873A1 (fr) 2020-07-24
PT3902800T (pt) 2022-11-16
RS64334B1 (sr) 2023-08-31
TW202043227A (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
MX2021008651A (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisomericamente enriquecido y metodo de preparacion y de purificacion.
ES8402591A1 (es) Procedimiento para la obtencion de pirazolooxacinas, pirazolotiacinas y pirazoloquinolinas.
MX2021008654A (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisomericamente enriquecido y metodo de sintesis.
CR20220312A (es) Compuestos tricíclicos sustituidos
TW200612892A (en) Novel compounds
EP0129128A3 (en) 2-pyrimidinyl-1-piperazine derivatives, process for their preparation and medicines containing them
TW200630336A (en) Novel compounds
NZ214407A (en) Tricyclic compounds and pharmaceutical compositions
TW200621690A (en) Novel compounds
DE3174844D1 (en) Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
TW200635942A (en) 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceurical preparations that contain the latter
TW200745003A (en) Novel compounds
SE0301009D0 (sv) Novel compounds
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
MX2020012691A (es) Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico.
PH12021550329A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
GEP20084470B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
MX2021012392A (es) Compuestos, composiciones y metodos.
CR20230223A (es) Composiciones farmacéuticas de un inhibidor de cinasa
MX2022001167A (es) Metodo para el tratamiento de una composicion que comprende vainillina natural.
ES8103112A1 (es) Procedimiento para la obtencion de pseudo-trisacaridos
MX2023007382A (es) Composiciones y métodos relacionados con compuestos que contienen biciclo [2.2.1] heptanamina di-sustituida.